Newsmeme!
Discover News you didn't know existed
Gene frequency
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Expert: Ovarian Cancer Screening Recommended Only for Women in High-risk Groups
Published July 8, 2009, 2:42 pm, Newswise
In an article published in The New England Journal of Medicine, UNC's Daniel Clarke-Pearson, M.D. reviews the current state of ovarian cancer screening and explains why it should be limited to women with indicators suggesting they are at high risk.
My Pharmiweb.com
Published July 8, 2009, 2:04 am, PharmiWeb
Lexington, Massachusetts, US – July 6th, 2009 – Shire plc (LSE: SHP, NASDAQ:SHPGY), the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher Disease patients, it has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in ...
Current Search For Heart Disease Treatment May Not Be Fruitful
Published July 7, 2009, 11:20 am, Science Daily
A protein used by doctors to indicate a patient's risk of coronary heart disease may have drug developers barking up the wrong treatment tree, according a new study. Their research suggests that C-reactive protein, an enticing target for scientists working on new treatments for coronary heart disease, may not have a role in causing the disease, even though it is a predictive marker.
Boca Raton woman part of emerging cancer treatment
Published July 7, 2009, 6:26 am, Boca Raton News
A local breast cancer patient was recommended by Boca Raton Community Hospital to participate in a newly developed treatment, according to Medical Oncologist at Lynn Cancer Institute, Louise Morrell. And some success was seen in the new therapy. Lynn Cancer Institute Medical Director Phillips Smith is ``fascinated by this novel therapy because it is a whole new avenue for cancer research.'' But ...
Shire Has Filed A Treatment Protocol For Velaglucerase Alfa For Gaucher Disease
Published July 7, 2009, 4:14 am, Medical News Today
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher Disease patients, it has filed a treatment protocol for ve
Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
Published July 6, 2009, 4:57 pm, redOrbit
LEXINGTON, Massachusetts, July 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher Disease patients, it has filed a treatment protocol for velaglucerase alfa, its enzyme ...
Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
Published July 6, 2009, 12:01 pm, PR Newswire via Yahoo! Finance
Shire plc , the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher Disease patients, it has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Gaucher Disease.
In Print
Published July 6, 2009, 9:17 am, GenomeWeb News
Ay F, Kahveci T, DE Crécy-Lagard V. A fast and accurate algorithm for comparative analysis of metabolic pathways . [ J Bioinform Comput Biol . 2009 Jun;7(3):389-428]: Describes an algorithm for pairwise alignment of metabolic pathways.
News Notes: Study Documents How HIV May Have Spread to Human Populations
Published July 6, 2009, 6:38 am, National Cancer Institute
Researchers at NCI and other institutes have documented how a mutation in an African population may have made them susceptible to infection by the human immunodeficiency virus (HIV) and related viruses.
Second gene linked to familial testicular cancer identified
Published July 6, 2009, 5:48 am, PharmaBiz
Specific variations or mutations in a particular can gene raise a man's risk of familial, or inherited, testicular germ-cell cancer, the most common form of this disease, according to new research by scientists at the National Institutes of Health.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |